Decision-tree sensitivity analysis for cost-effectiveness of chest 2- fluoro-2-D-[18F]fluorodeoxyglucose positron emission tomography in patients with pulmonary nodules (non-small cell lung carcinoma) in Japan

Chest

Volumn 117, Issue 2, 2000, Pages 346-353

  Kosuda, Shigeru ^a   Ichihara, Kiyoshi ^b   Watanabe, Masumi ^a   Kobayashi, Hideo ^a   Kusano, Shoichi ^c  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c NONE

Author keywords

2 fluoro 2 D 18F fluorodeoxyglucose positron emission tomography; Cost effectiveness; Life expectancy non small cell lung carcinoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; HUMAN; JAPAN; LIFE EXPECTANCY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 0033999947     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.117.2.346     Document Type: Article

References (53)

1. 1 Gambhir SS, Hoh CK, Phelps ME, et al. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J Nucl Med 1996; 37:1428-1436
2. 2 Weber W, Bulow H, Romer W, et al. FDG-PET in solitary pulmonary nodules: a German cost-effectiveness analysis [abstract]. J Nucl Med 1997; 38(suppl):245p
3. 3 Gambhir SS, Shepherd J, Phelps ME, et al. A theoretical decision analysis model for the cost effectiveness of newly emerging coincidence imaging (CI) technology in the presurgicaal staging of non-small cell lung carcinoma (NSCLC) [abstract]. J Nucl Med 1997; 38(suppl):245p
4. 4 Steinert HC, von Schulthess GK, Weder W. Effectiveness of whole-body FDG PET in staging of non-small-cell lung cancer (NSCLC) [abstract]. J Nucl Med 1998; 39(suppl):80p
5. 5 Kubota K, Yamada S, Fukuda H, et al. Cost effectiveness analysis of FDG-PET in the differential diagnosis and staging of lung cancer in Japan. Kaku Igaku (Jpn J Nucl Med) 1997; 34:329-336
6. 6 Ell PJ. Challenges for nuclear medicine in the 1990s. Nucl Med Commun 1992; 13:65-75
7. 7 Kosuda S, Ichihara K, Watanabe M, et al. Decision tree sensitivity analysis for cost-effectiveness of chest FDG-PET in patients with a pulmonary tumor (non-small cell carcinoma). Kaku Igaku (Jpn J Nucl Med) 1998; 35:395-404
8. 8 Weinstein MC, Fineberg HV. Clinical decision analysis. Philadelphia, PA: WB Saunders, 1980
9. 9 Pauker S, Kassirer J. The threshold approach to clinical decision making. N Engl J Med 1980; 302:1109-1117
10. 10 Luce B, Simpson K. Methods of cost-effectiveness analysis: areas of consensus and debate. Clin Therap 1995; 17:109-125
11. 11 Kubota K, Matsuzawa T, Fujiwara T, et al. Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med 1990; 31:1927-1932
12. 12 Jacobs MP, Mantil JC, Peterson CD, et al. FDG PET imaging of the chest. J Nucl Med 1992; 33(suppl):975-976
13. 13 Knopp MV, Bishoff H, Oberdorfer F, et al. Positron emission tomography of the thorax: the current clinical status. Radiology 1992; 32:290-295
14. 14 Slosman DO, Spiliopoulos A, Couson F, et al. Satellite PET and lung cancer: a prospective study in surgical patients. Nucl Med Commun 1993; 14:955-961
15. 15 Scott WJ, Schwabe JL, Gupta NC, et al. Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F]fluoroglucose: the members of the PET-lung tumor study group. Ann Thorac Surg 1994; 58:698-703
16. 16 Duhaylongsod FG, Lowe VJ, Patz EJ Jr, et al. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography. J Thorac Cardiovasc Surg 1995; 110:130-139
17. 17 Hubner KF, Buonocore E, Singh SK, et al. Characterization of chest masses by FDG positron emission tomography. Clin Nucl Med 1995; 20:293-298
18. 18 Sazon DA, Santiago SM, Soo Hoo GW, et al. Fluorodeoxy-glucose-positron emission tomography in the detection and staging of lung cancer. Am J Respir Crit Care Med 1996; 153:417-421
19. 19 Weber W, Romer W, Ziegler S, et al. F-18-FDG PET in the evaluation of small solitary pulmonary nodules [abstract]. J Nucl Med 1996; 37(suppl):111p
20. 20 Bury T, Dowlati A, Paulus P, et al. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur Respir J 1996; 9:410-414
21. 21 Gross B, Glazer G, Orringer M, et al. Bronchogenic carcinoma metastatic to normal-sized lymph nodes: frequency and significance. Radiology 1988; 166:71-74
22. 22 Webb W, Gatsonis G, Zerhouni E, et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology 1991; 178:705-713
23. 23 McLoud TC, Bourgouin PM, Greenberg RW, et al. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology 1992; 182:319-323
24. 24 Seely JM, Mayo JR, Miller RR, et al. T1 lung cancer: prevalence of mediastinal nodal metastasis and diagnostic accuracy of CT. Radiology 1993; 186:129-132
25. 25 White P, Adams H, Crane M, et al. Preoperative staging of carcinoma of the bronchus: can computed tomographic scanning reliably identify stage tumors? Thorax 1994; 49:951-957
26. 26 Primack S, Lee K, Logan P. Bronchogenic carcinoma: utility of CT in the evaluation of patients with suspected lesions. Radiology 1994; 193:795-800
27. 27 Dillemans B, Deneffe G, Verschakelen J, et al. Value of computed tomography and mediastinoscopy in preoperative evaluation of mediastinal nodes in non-small cell lung cancer. Eur J Cardiothorac Surg 1994; 8:37-42
28. 28 Yokoi K, Okuyama A, Mori K. Mediastinal lymph node metastasis from lung cancer: evaluation with 201 Tl-SPECT; comparison with CT. Radiology 1994; 192:813-817
29. 29 Wahl RL, Quint L, Greenough R, et al. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994; 191:371-377
30. 30 Madar I, Hoh C, Figlin R, et al. Cost-effective staging of non-small-cell lung carcinoma by whole-body PET-FDG imaging [abstract]. J Nucl Med 1995; 36(suppl):57p
31. 31 Valk P, Pounds T, Hopkins D, et al. Staging of lung cancer by whole-body PET-FDG imaging [abstract]. J Nucl Med 1995; 36(suppl):95p
32. 32 Williams D, Paircolero P, Davis C, et al. Survival of patients surgically treated for stage I lung cancer. J Thorac Cardiovasc Surg 1981; 82:70-76
33. 33 Evans E. Resection of bronchial carcinoma in the elderly. Thorax 1973; 28:86-88
34. 34 Ginsberg R, Hill I, Eagan R, et al. Modern thirty-day operative mortality for surgical resection in lung cancer. J Thorac Cardiovasc Surg 1983; 86:654-658
35. 35 Black WC, Armstrong P, Daniel T. Cost-effectiveness of chest CT in T1N0M0 lung cancer. Radiology 1988; 167:373-378
36. 36 Moroff S, Pauker S. What to do when the patient outlives the literature, or DEALE-ing with a full deck. Med Decis Making 1983; 3:313-338
37. 37 Cummings S, Illington G, Richard R. Managing solitary pulmonary nodules: the choice of strategy in a "close call." Am Rev Respir Dis 1986; 134:453-460
38. 38 Hartman G, Hattery R, Witten D, et al. Mortality during excretory urography: Mayo Clinic experience. AJR Am J Roentgenol 1982; 139:914-922
39. 39 McClennan B. Low-osmolality contrast media: premises and promises. Radiology 1987; 162:1-8
40. 40 Beck J, Kassirer J, Pauker S. A convenient approximation of life expectancy (the "DEALE"): I. Validation of the method. Am J Med 1982; 73:883-888
41. 41 Beck J, Pauker S, Gottlieb J. A convenient approximation of life expectancy (the "DEALE"): II. Use in medical decision-making. Am J Med 1982; 73:889-897
42. 42 Kitagawa T. Radiotherapy. In: Ishikawa S, ed. Clinical lung cancer [in Japanese]. Tokyo, Japan: Kohdansha, 1983; 189-229
43. 43 Proto AV, Thomas SR. Pulmonary nodules studied by computed tomography. Radiology 1985; 156:149-153
44. 44 Zerhouni EA, Stitik FP, Siegelman SS, et al. CT of the pulmonary nodule: a cooperative study. Radiology 1986; 160:319-327
45. 45 Siegelman SS, Khouri NF, Leo FP, et al. Solitary pulmonary nodules: CT assessment. Radiology 1986; 160:307-312
46. 46 Huston J 3d, Muhm JR. Solitary pulmonary nodules: evaluation with a CT reference phantom. Radiology 1989; 170:653-656
47. 47 Sasaki Y. Assessment of cost-effective nuclear medicine practice in Japan. Acad Radiol 1996; 3:S106-S108
48. 48 Motoyama A, Kono M, Adachi S, et al. Secondary screening for lung cancer by helical CT [in Japanese]. Jpn J Lung Cancer 1995; 35:883-890
49. 49 Yamanda T, Miyazawa M, Kondo R, et al. Analysis of small peripheral pulmonary tumors treated by thoracoscopic excisional biopsy (wedge resection) on a suspicion of primary lung cancer [in Japanese]. Jpn J Lung Cancer 1999; 39:137-143
50. 50 Nomori H, Horio H, Fuyuno G, et al. Analysis of reasons for biopsy in small pulmonary nodules diagnosed by thoracoscopic and open-lung biopsy [in Japanese]. Jpn J Lung Cancer 1999; 39:35-41
51. 51 Wahl RL. Positron emission tomography: applications in oncology. In: Henkin RB, et al, ed. Nuclear medicine. St. Louis, MO: Mosby, 1996; 1524-1545
52. 52 Ito S, Koyama S, Tusaka M, et al. Fundamental study for lung-cancer screening by helical CT: first report; evaluation of radiation dose and image quality using a phantom. Nippon Igaku Hoshasen Gakkai Zasshi (Nippon Acta Radiol) 1996; 56:731-35
53. 53 Sone S, Takashima S, Li F, et al. Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet 1998; 351:1242-1245